Prostate carcinoma presentation, diagnosis, and staging: An update from the National Cancer Data Base

Cancer

Volumn 98, Issue 6, 2003, Pages 1169-1178

  Miller, David C ^a   Hafez, Khaled S ^a   Stewart, Andrew ^b   Montie, James E ^a   Wei, John T ^a,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b AMERICAN COLLEGE OF SURGEONS   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Diagnosis; Prostate carcinoma; Screening; Staging

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ANTIGEN SPECIFICITY; BIOPSY TECHNIQUE; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER SCINTISCANNING; CANCER STAGING; CLINICAL FEATURE; DATA BASE; DEMOGRAPHY; EVALUATION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PATIENT CARE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; REVIEW; RISK ASSESSMENT; SYMPTOMATOLOGY; TRANSRECTAL ULTRASONOGRAPHY; TUMOR DIAGNOSIS; TUMOR DIFFERENTIATION;

AGED; BIOPSY; DATABASES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 0041415826     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11635     Document Type: Review

References (42)

1. Schmidt JD, Mettlin CJ, Natarajan N, et al. Trends in patterns of care for prostatic cancer, 1974-1983: results of surveys by the American College of Surgeons. J Urol. 1986;136: 416-421.
2. Mettlin CJ, Murphy GP, Cunningham MP, et al. The National Cancer Data Base report on race, age, and region variations in prostate cancer treatment. Cancer. 1997;80: 1261-1266.
3. Mettlin CJ, Murphy GP, Sylvester J, et al. Results of hospital cancer registry surveys by the American College of Surgeons: outcomes of prostate cancer treatment by radical prostatectomy. Cancer. 1997;80:1875-1881.
4. Mettlin CJ, Murphy GP, Babaian RJ, et al. Observations on the early detection of prostate cancer from the American Cancer Society National Prostate Cancer Detection Project. Cancer. 1997;80:1814-1817.
5. Mettlin CJ, Murphy GP, Ho R, et al. The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer. 1996;77:2162-2166.
6. Mettlin CJ, Murphy GP, McGinnis LS, et al. The National Cancer Data Base report on prostate cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1995;76:1104-1112.
7. Mettlin CJ, Murphy GP, Rosenthal DS, et al. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83:1679-1684.
8. O'Dowd GJ, Veltri RW, Orozco R, et al. Update on the appropriate staging evaluation for newly diagnosed prostate cancer. J Urol. 1997;158:t-98.
9. Mettlin CJ, Menck HR, Winchester DP, et al. A comparison of breast, colorectal, lung, and prostate cancers reported to the National Cancer Data Base and the Surveillance, Epidemiology, and End Results Program. Cancer. 1997;79:2052-2061.
10. World Health Organization. International classification of diseases for oncology, 2nd ed. Geneva: World Health Organization, 2002.
11. Fleming ID, Cooper JS, Henson DE. AJCC cancer staging handbook, 5th ed. Philadelphia: Lippincott-Raven, 1998.
12. Bahnson RR, Hanks GE, Huben RP, et al. NCCN practice guidelines for prostate cancer. Oncology (Huntington). 2000; 14:111-119.
13. Carroll P, Coley C, McLeod D, et al. Prostate-specific antigen best practice policy - part II: prostate cancer staging and post-treatment follow-up. Urology. 2001;57:225-229.
14. Smith DS, Humphrey PA, Catalona WJ. The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience. Cancer. 1997;80:1852-1856.
15. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA. 1996;276:1309-1315.
16. Humphrey PA, Keetch DW, Smith DS, et al. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol. 1996;155:816-820.
17. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol. 1994;152:t-6.
18. Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948-954.
19. Hoedemaeker RF, Rietbergen JB, Kranse R, et al. Histopathological prostate cancer characteristics at radical prostatectomy after population based screening. J Urol. 2000;164:411-415.
20. Van Der Cruijsen-Koeter IW, Roobol M, Damhuis RA, et al. Comparison of screen detected and clinically diagnosed prostate cancer in the 'European Randomized Study of Screening for Prostate Cancer'. J Urol. 2002;167(4, Suppl): 102.
21. Andriole GL, Catalona WJ. Using PSA to screen for prostate cancer. The Washington University experience. Urol Clin North Am. 1993;20:647-651.
22. Feuer EJ, Mariotto A, Merrill R. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates. Cancer. 2002;94:870-880.
23. Labrie F. Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support. Prostate. 2000;43:215-222.
24. Labrie F, Candas B, Dupont A, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate. 1999;38: 83-91.
25. Carroll P, Coley C, McLeod D, et al. Prostate-specific antigen best practice policy - part I: early detection and diagnosis of prostate cancer. Urology. 2001;57:217-224.
26. Fowler FJ Jr., Bin L, Collins MM, et al. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. Am J Med. 1998;104:526-532.
27. O'Leary MP, Baum NH, Blizzard R, et al. 2001 American Urological Association Gallup Survey: changes in physician practice patterns, satisfaction with urology, and treatment of prostate cancer and erectile dysfunction. J Urol. 2002; 168:649-652.
28. Fowler JE Jr., Bigler SA, Farabaugh PB. Prospective study of cancer detection in black and white men with normal digital rectal examination but prostate specific antigen equal or greater than 4.0 ng/mL. Cancer. 2002;94:1661-1667.
29. Fowler JE Jr., Bigler SA, Farabaugh PB, et al. Prostate cancer detection in black and white men with abnormal digital rectal examination and prostate specific antigen less then 4 ng/ml. J Urol. 2000;164:1961-1963.
30. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445-1451.
31. Epstein JI, Partin AW, Sauvageot J, et al. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol. 1996;20:286-292.
32. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer. JAMA. 1994;271:368-374.
33. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer. 1993;71:3582-3593.
34. Stamey TA, Freiha FS, McNeal JE, et al. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993 (Suppl 8);71.
35. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330:242-248.
36. Albertsen PC, Hanley JA, Gleason DF, et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280:975-980.
37. Scherr DS, Eastham J, Ohori M, Scardino PT. Prostate biopsy techniques and indications: when, where, and how? Semin Urol Oncol. 2002;20:18-31.
38. Epstein JI, Potter SR. The pathological interpretation and significance of prostate needle biopsy findings: implications and current controversies. J Urol. 2001;166:402-410.
39. Cooperberg MR, Lubeck DP, Grossfeld GD, et al. Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor. J Urol. 2002;168:491-495.
40. Barry MJ, Fowler FJ Jr., Bin L, et al. A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer. J Urol. 1997;158:488-491.
41. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Controlled Clin Trials. 2000;21:273S-309S.
42. De Koning HJ, Liem MK, Baan CA, et al. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial. Int J Cancer. 2002;98:268-273.